Stay updated with breaking news from Mia Levy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 14, 2023--
The FDA has approved FoundationOne CDx to be utilized as a companion diagnostic for the dual-action tablet of niraparib plus abiraterone acetate, which was approved for use in combination with prednisone in adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
/PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, has launched the SPARK Study to...
'In Israel, you learn from experts on the ground who are working in this area every day'.